By a News Reporter-Staff News Editor at Clinical Trials Week Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced that on August 29, dosing commenced of the first patients enrolled in the Company's Phase 3 registration trial
By a News Reporter-Staff News Editor at Clinical Trials Week Aerie Pharmaceuticals, Inc. announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September 10, 2014 at 12:00p.m. ET in New York, NY. About Aerie Pharmaceuticals, Inc. Aerie is a clinical-stage pharmaceutical company focused on the discov
By a News Reporter-Staff News Editor at Clinical Trials Week Allergan, Inc. announced that the European Commission has extended the Marketing Authorization for OZURDEX to treat adult patients with visual impairment due to diabetic macular edema who are pseudophakic, or who are considered insufficiently responsive to, or unsuitable for...
Amgen today announced data from the Phase 3 SHIFT study evaluating ivabradine in patients with chronic heart failure were presented at the 18 th Annual Scientific Meeting of the Heart Failure Society of America in Las Vegas. "Despite standard of care, chronic heart failure remains a disabling condition with a poor prognosis for patients at risk
Amgen Submits Marketing Authorization Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The European Medicines Agency. By a News Reporter-Staff News Editor at Clinical Trials Week Amgen announced the submission of a Marketing Authorization Application to the European Medicines Agency via the centralized...
From June 2011 until February 2014, Dr. Wierenga served as Executive Vice President, Research and Development of Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in January 2014. From 2003 to 2007, Dr. Wierenga served as Executive Vice President, Research and Development of Neurocrine Biosciences,
Avanir Pharmaceuticals, Inc. today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. "This is an exciting advancement in Alzheimer's disease research," said Jeffrey Cummings, MD, director of the Cleveland Clinic Lou Ruvo Cen
WASHINGTON- Avanir Pharmaceuticals, Inc. announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. The company said the treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, t
By a News Reporter-Staff News Editor at Clinical Trials Week BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Eric K. Rowinsky, M.D., currently se
BioMarin Pharmaceutical Inc. today announced that CenterWatch, a leading source for global clinical trial information, has named it one of the fastest drug developers in the industry. CenterWatch reviewed 307 therapies approved between 2000 and 2013 and concluded that BioMarin ranked within the top five in all categories. For the patients we seek
Boston Strategics Corporation Initiates a Phase 1 Clinical Trial of the Anti-cancer Agent "FF-10501" for FUJIFILM in Patients with Advanced Hematologic Malignancies. By a News Reporter-Staff News Editor at Clinical Trials Week Boston Strategics Corporation, a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A.,.
Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Ariz., reported that it will launch 12 additional industry-sponsored clinical trials from now through December. "These research studies further our mission at CTCA to improve overall cancer care, providing additional, innovative treatment options for our patients,"
Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the publication of preclinical data in Pediatric Blood& Cancer that further characterize the therapeutic potential of lead compound CPX-351 in hematological malignancies and support its ongoing clinical testing in..
By a News Reporter-Staff News Editor at Clinical Trials Week Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced that it has received two separate Orphan Drug Designations from the European Medicines Agency for th
Cleveland BioLabs, Inc. today announced approval from the Ministry of Health of the Russian Federation to start a Phase 1 clinical trial with CBLB612, a drug in development for the induction and mobilization of hematopoietic stem cells. This study is partially funded through a contract from the Ministry of Industry and Trade of the Russian Federati
Clovis Oncology reported that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site. In its release, Clovis Oncology said Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 and 2, vascu
Cochlear Limited, the global leader in implantable hearing solutions, announced today that the US Food and Drug Administration approved the use of 2.4 GHz wireless connectivity with the Cochlear? Nucleus 6 Sound Processor. The Cochlear Wireless portfolio includes three accessories designed to help bring Nucleus 6 System recipients closer to
Mukesh Kumar will be held on October 16-17, 2014 in Durham, North Carolina. This seminar will provide step by step instructions to create SOPs for FDA- regulated organizations based on the instructor's extensive FDA compliance training experience. He has been a part of over 100 clinical trials in more than 40 countries, presented hundreds of US FDA
Data on Cancer Gene Therapy Detailed by Researchers at Baylor University College of Medicine. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "Recent advances in imaging techniques provide innovative tools for the detection of bladder cancer. Our news journalists obtained a quote from the research from
Data on Health and Society Reported by Researchers at Boston University. Our news journalists obtained a quote from the research from Boston University, "We found that drugs approved after the act's passage were more likely to receive a new black-box warning or be withdrawn than drugs approved before its passage. The news correspondents report that
By a News Reporter-Staff News Editor at Clinical Trials Week DelMar Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office has issued a notice of allowance for patent application number 13/ 933,751, covering improved methods for synthesizing VAL-083, DelMar's lead drug candidate, which is currently in a Phase I/II clin
By a News Reporter-Staff News Editor at Clinical Trials Week Fresh data on Therapeutics are presented in a new report. According to news reporting originating in Louisville, Kentucky, by NewsRx journalists, research stated, "In human cancers, loss of PTEN, stabilization of hypoxia inducible factor-1? The news reporters obtained a quote from the r
The FDA recently approved Contrave, a weight loss drug being marketed for those who are obese and have, at least, one other accompanying illness. Clinical trial results included patients without diabetes and revealed that 42 percent of the patients treated with Contrave lost at least 5% of their body weight in comparison to 17% for patients who w
By a News Reporter-Staff News Editor at Clinical Trials Week Regulatory News: ERYTECH Pharma, the French biopharmaceutical company that develops innovative' tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board completed its second sa
By a News Reporter-Staff News Editor at Clinical Trials Week Exelixis, Inc. announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide.